Brief: Reviva Pharmaceuticals Announces First Patients Dosed In Pivotal Phase 3 Study

Reviva Pharmaceuticals Holdings

01/02/2022 11:01

Feb 1 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA PHARMACEUTICALS ANNOUNCES FIRST PATIENTS DOSED IN
PIVOTAL
PHASE 3 STUDY AND LONG-TERM SAFETY TRIAL EVALUATING
BRILAROXAZINE FOR THE TREATMENT OF SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - ANTICIPATES
EXPANDING
CLINICAL DEVELOPMENT OF BRILAROXAZINE INTO OTHER
NEUROPSYCHIATRIC INDICATIONS

Source text for Eikon:  ID:nGNX52LPrc 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))